Market Cap 2.45M
Revenue (ttm) 4.49M
Net Income (ttm) -29.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -662.36%
Debt to Equity Ratio 0.00
Volume 14,571,800
Avg Vol 3,131,146
Day's Range N/A - N/A
Shares Out 26.01M
Stochastic %K 5%
Beta 0.94
Analysts Strong Sell
Price Target $7.00

Company Profile

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 495 2200
Fax: 609 495 2202
Website: palatin.com
Address:
Cedar Brook Corporate Center, 4-B Cedar Brook Drive, Cranbury, United States
WallStWireAds
WallStWireAds Jul. 15 at 10:24 PM
$PTN https://www.benzinga.com/pressreleases/25/07/ab46431057/palatins-oral-obesity-drug-shows-remarkable-results-the-hidden-gem-in-the-weight-loss-race
0 · Reply
WallStWireAds
WallStWireAds Jul. 15 at 11:53 AM
$PTN https://www.prnewswire.com/news-releases/palatin-announces-positive-preclinical-efficacy-data-for-oral-mc4r-agonist-pl7737-in-animal-model-of-obesity-302505219.html
0 · Reply
PsychedeliX
PsychedeliX Jul. 13 at 12:57 PM
$PTN i see some filling from insiders
1 · Reply
Aaron0321
Aaron0321 Jul. 8 at 4:12 PM
$PTN how should we be voting guys? Who can break it down Barney style?!?!
0 · Reply
AHHunter
AHHunter Jul. 5 at 5:20 PM
$PTN A previous posting, a day or two ago on 9643 was incorrect. The state of affairs on the matters is, to quote from a PTNT release. “Next Steps in the Phase 3 PL9643 Program: The remaining Phase 3 program includes two additional studies, MELODY-2 and MELODY-3, which will evaluate both signs and symptoms of DED. Pending partnership and funding, enrollment could begin in the second half of 2025, with topline data anticipated in the second half of 2026. DED Market Opportunity: DED affects approximately 38 million people in the U.S., but fewer than 10% receive prescription treatment. The market is expected to grow from $6.1 billion in 2024 to $7.5 billion by 2029.”
0 · Reply
Stocks787
Stocks787 Jul. 4 at 11:46 AM
$PTN According to the most recent information, the Phase 3 clinical trial of PL9643 for dry eye, called MELODY-1, completed its final patient visit in February 2024. The study's primary results demonstrated statistically significant improvements in dry eye symptoms compared to placebo. Palatin Technologies is currently analyzing the study data and plans to meet with the FDA to discuss next steps for potential approval of PL9643. If the FDA approves the drug, it could be available to patients in the near future.
0 · Reply
Stocks787
Stocks787 Jul. 4 at 11:44 AM
$PTN Of course, PL9643 differs from existing dry eye medications because it works in a different way. Instead of just lubricating the eye or reducing inflammation, PL9643 stimulates melanocortin receptors. These receptors are part of the body's natural system for maintaining eye health. By stimulating them, PL9643 could provide faster and longer-lasting symptom relief compared to current treatments.
0 · Reply
JOHNB21400
JOHNB21400 Jul. 3 at 3:49 PM
$PTN Heavy Volume
0 · Reply
Stocks787
Stocks787 Jun. 29 at 5:47 PM
$PTN 🚀🚀🚀🚀🚀🚀🚀🚀🚀
0 · Reply
AHHunter
AHHunter Jun. 27 at 9:01 AM
$PTN $XIACF CHINA'S XIAOMI RECEIVES ALMOST 300,000 SUV PRE-ORDERS IN MINUTES The exceptionally strong initial orders for Xiaomi's YU7 electric sport utility vehicle fanned speculation that Tesla may have to cut prices to fight back. BEIJING: Chinese electric vehicle maker Xiaomi received almost 300,000 pre-orders within an hour for its first sports utility vehicles in what the company said was a "miraculous" moment for the industry. Lei Jun, founder and CEO of the electronics-turned-car company, said he was astonished by the reaction from customers. "My goodness, in just two minutes, we received 196,000 paid pre-orders and 128,000 lock-in orders," Lei said in a video distributed after the vehicle's launch on Thursday night (Jun 26). "We may be witnessing a miracle in China's automotive industry."
1 · Reply
Latest News on PTN
Palatin Appeals NYSE American Notice of Delisting

Apr 14, 2025, 7:00 AM EDT - 3 months ago

Palatin Appeals NYSE American Notice of Delisting


Palatin Provides Update on Anticipated 2025 Corporate Milestones

Jan 28, 2025, 7:30 AM EST - 6 months ago

Palatin Provides Update on Anticipated 2025 Corporate Milestones


Palatin Receives Notice of Non-Compliance from NYSE American

Oct 7, 2024, 4:15 PM EDT - 10 months ago

Palatin Receives Notice of Non-Compliance from NYSE American


Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results

Sep 26, 2024, 7:30 AM EDT - 10 months ago

Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results


WallStWireAds
WallStWireAds Jul. 15 at 10:24 PM
$PTN https://www.benzinga.com/pressreleases/25/07/ab46431057/palatins-oral-obesity-drug-shows-remarkable-results-the-hidden-gem-in-the-weight-loss-race
0 · Reply
WallStWireAds
WallStWireAds Jul. 15 at 11:53 AM
$PTN https://www.prnewswire.com/news-releases/palatin-announces-positive-preclinical-efficacy-data-for-oral-mc4r-agonist-pl7737-in-animal-model-of-obesity-302505219.html
0 · Reply
PsychedeliX
PsychedeliX Jul. 13 at 12:57 PM
$PTN i see some filling from insiders
1 · Reply
Aaron0321
Aaron0321 Jul. 8 at 4:12 PM
$PTN how should we be voting guys? Who can break it down Barney style?!?!
0 · Reply
AHHunter
AHHunter Jul. 5 at 5:20 PM
$PTN A previous posting, a day or two ago on 9643 was incorrect. The state of affairs on the matters is, to quote from a PTNT release. “Next Steps in the Phase 3 PL9643 Program: The remaining Phase 3 program includes two additional studies, MELODY-2 and MELODY-3, which will evaluate both signs and symptoms of DED. Pending partnership and funding, enrollment could begin in the second half of 2025, with topline data anticipated in the second half of 2026. DED Market Opportunity: DED affects approximately 38 million people in the U.S., but fewer than 10% receive prescription treatment. The market is expected to grow from $6.1 billion in 2024 to $7.5 billion by 2029.”
0 · Reply
Stocks787
Stocks787 Jul. 4 at 11:46 AM
$PTN According to the most recent information, the Phase 3 clinical trial of PL9643 for dry eye, called MELODY-1, completed its final patient visit in February 2024. The study's primary results demonstrated statistically significant improvements in dry eye symptoms compared to placebo. Palatin Technologies is currently analyzing the study data and plans to meet with the FDA to discuss next steps for potential approval of PL9643. If the FDA approves the drug, it could be available to patients in the near future.
0 · Reply
Stocks787
Stocks787 Jul. 4 at 11:44 AM
$PTN Of course, PL9643 differs from existing dry eye medications because it works in a different way. Instead of just lubricating the eye or reducing inflammation, PL9643 stimulates melanocortin receptors. These receptors are part of the body's natural system for maintaining eye health. By stimulating them, PL9643 could provide faster and longer-lasting symptom relief compared to current treatments.
0 · Reply
JOHNB21400
JOHNB21400 Jul. 3 at 3:49 PM
$PTN Heavy Volume
0 · Reply
Stocks787
Stocks787 Jun. 29 at 5:47 PM
$PTN 🚀🚀🚀🚀🚀🚀🚀🚀🚀
0 · Reply
AHHunter
AHHunter Jun. 27 at 9:01 AM
$PTN $XIACF CHINA'S XIAOMI RECEIVES ALMOST 300,000 SUV PRE-ORDERS IN MINUTES The exceptionally strong initial orders for Xiaomi's YU7 electric sport utility vehicle fanned speculation that Tesla may have to cut prices to fight back. BEIJING: Chinese electric vehicle maker Xiaomi received almost 300,000 pre-orders within an hour for its first sports utility vehicles in what the company said was a "miraculous" moment for the industry. Lei Jun, founder and CEO of the electronics-turned-car company, said he was astonished by the reaction from customers. "My goodness, in just two minutes, we received 196,000 paid pre-orders and 128,000 lock-in orders," Lei said in a video distributed after the vehicle's launch on Thursday night (Jun 26). "We may be witnessing a miracle in China's automotive industry."
1 · Reply
buysellrepeat
buysellrepeat Jun. 25 at 6:02 AM
$PTN how the f does this guy have more followers than wtf 0
0 · Reply
Stocks787
Stocks787 Jun. 24 at 3:42 PM
$PTN weekly shopping, what you have to have is patience. 🚀🚀🚀😴😴😴😴
0 · Reply
Stocks787
Stocks787 Jun. 23 at 5:33 PM
$PTN Does anyone know that they keep buying it?
0 · Reply
JOHNB21400
JOHNB21400 Jun. 20 at 6:39 PM
$PTN 16 on good volume. 1. Submit dry eye results to the FDA 2. Start phase three on the other two drugs. 3. Collect more money from Script Inc. 4. Secure partnerships 5. That should take it to $7.00
1 · Reply
StocksCC
StocksCC Jun. 20 at 11:18 AM
$PTN will PTN be available on german exchanges again?
1 · Reply
Walterminty
Walterminty Jun. 19 at 10:43 AM
0 · Reply
JOHNB21400
JOHNB21400 Jun. 18 at 5:53 PM
$PTN 16.5 and rising.
0 · Reply
JOHNB21400
JOHNB21400 Jun. 18 at 3:59 PM
$PTN High of 14 so far.
0 · Reply
MrTicker
MrTicker Jun. 18 at 3:47 PM
$PTN nice under the radar uptrend towards that .20+ level
0 · Reply
MasterOfMyDomains
MasterOfMyDomains Jun. 18 at 3:43 PM
$PTN Hmnmm
0 · Reply
JOHNB21400
JOHNB21400 Jun. 18 at 3:42 PM
$PTN 13.5 and up
0 · Reply
JOHNB21400
JOHNB21400 Jun. 18 at 3:41 PM
$PTN 13 and moving up
0 · Reply